[A25-139] Momelotinib (myelofibrosis) – Benefit assessment according to §35a Social Code Book V
Last updated 02.02.2026
Project no.:
A25-139
Commission:
Commission awarded on 04.11.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
The treatment of disease-related splenomegaly or symptoms in adults with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis
- Patients who are JAK inhibitor naïve: added benefit not proven
- Patients who have been treated with ruxolitinib: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-139
| Project no. | Title | Status |
|---|---|---|
| G24-04 | Momelotinib (myelofibrosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |